Loading
A phase 3 trial of PM8002, Durvalumab in non-small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) is a phase 3 interventional study registered as NCT07361497 by Bristol-Myers Squibb, with 850 participants planned, started 2026-03-16 and due to reach its primary completion in 2030-09-18. Interventions recorded: Pumitamig, Durvalumab. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
Shares PM8002, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Unresectable stage III non-small-cell lung cancer, Durvalumab, Immune checkpoint inhibitors.
Shares Unresectable stage III non-small-cell lung cancer, Durvalumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Immune checkpoint inhibitors.
Shares Unresectable stage III non-small-cell lung cancer, Durvalumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/